Invion links with Hovione on inhaled zafirlukast

27 July 2015

Australian drug developer Invion (ASX: IVX) has secured a commitment from Hovione Scientia, an Ireland-based unit of Portuguese drugmaker Hovione, to progress development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Invion and Hovione will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler. Zafirlukast is the active ingredient of AstraZeneca's asthma drug Accolate.

Invion has an exclusive, worldwide licence to develop and commercialize all inhaled formulations and applications of zafirlukast. The global market for asthma therapeutics is in excess of $22 billion per year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK